New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareExenatide vs Livagen

Exenatide vs Livagen

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss AgonistsCognitive Enhancement
Exenatide
Anti-Aging & Longevity
Livagen
Summary
Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Half-Life
~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
Short (minutes); gene-regulatory effects are sustained
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
5 mcg, titrate to 10 mcg
10 mg per day
Frequency
Twice daily
Daily for 10–30 days
Key Benefits
  • Blood glucose control in type 2 diabetes
  • Weight loss (average 2–3 kg in clinical trials)
  • Once-weekly extended-release formulation available
  • Reduces appetite and food intake
  • Possible neuroprotective in Parkinson's disease (Phase II trials)
  • Reduces systemic inflammation
  • May protect pancreatic beta cells
  • Cardiovascular neutral or potentially protective
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
Side Effects
  • Nausea (most common, especially initially)
  • Vomiting
  • Diarrhea
  • Headache
  • +4 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
Stacks With